文献速递核素与放射性配体治疗神经核医学

琥珀酰明胶可提升放射性标记Exendin-4在胰岛素瘤中的诊疗潜力

Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
PubMed 文献 · J Nucl Med · 2018-11-30

研究在10名健康志愿者中采用交叉设计,比较琥珀酰明胶(Gelofusine)与生理盐水对111In-exendin-4肾脏摄取的影响,并基于5例胰岛素瘤患者图像进行剂量学估算。结果显示Gelofusine使肾脏摄取降低18.1%,胰腺摄取不变,估算胰岛素瘤吸收剂量为30.3至127.8 Gy,使用Gelofusine后最高可提升至156.1 Gy。

要点

  • Gelofusine使111In-exendin-4肾脏摄取降低18.1%,胰腺摄取不变。
  • 3/10受试者肾脏摄取降低后胰尾与肾脏信号区分更佳。
  • 估算胰岛素瘤吸收剂量30.3–127.8 Gy,用Gelofusine后最高156.1 Gy。

核心结论

  • Gelofusine可降低111In-exendin-4在人体肾脏的摄取,有助于提高胰腺尾部的定性和定量分析准确性。
  • 该降低肾脏摄取的作用可支持向GLP-1R阳性肿瘤安全递送更高辐射剂量用于治疗。

研究设计与样本

  • 交叉设计研究,10名健康志愿者接受50 MBq 111In-exendin-4联合Gelofusine或生理盐水,24小时后行SPECT/CT,3周后重复。
  • 使用5例胰岛素瘤患者的平面闪烁显像111In-exendin图像进行剂量学估算。

主要发现

  • Gelofusine使111In-exendin-4肾脏摄取降低18.1%,胰腺摄取保持不变。
  • 10名受试者中3名肾脏摄取降低至可更好区分胰尾与肾脏信号。
  • 剂量学估算胰岛素瘤吸收剂量范围为30.3至127.8 Gy,使用Gelofusine后最高可增至156.1 Gy。

临床怎么用

  • 在放射性标记exendin诊疗中可考虑联合Gelofusine以降低肾脏摄取、改善胰尾区图像判读。
  • 若将放射性标记exendin用于肽受体放射性核素治疗,Gelofusine可能支持向GLP-1R阳性肿瘤递送更高安全剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Being highly expressed in insulinomas, the glucagonlike peptide-1 receptor (GLP-1R) is a potential target for diagnosis, localization, and treatment with the radiolabeled GLP-1R agonist exendin. Tracer accumulation in the kidneys, however, hampers accurate diagnostic visualization of pancreatic tissue and prohibits the therapeutic application of radiolabeled exendin for β-cell-derived tumors. Therefore, we evaluated the ability of succinylated gelatin (Gelofusine) to reduce the renal accumulation of radiolabeled exendin in humans, and we performed dosimetric calculations to estimate the maximum absorbed insulinoma dose that could be achieved if exendin were to be used for peptide receptor radionuclide therapy. Methods: Ten healthy volunteers received 50 MBq of 111In-exendin-4, in combination with Gelofusine or saline, in a crossover design. SPECT/CT images were obtained after 24 h. The procedure was repeated 3 wk later. Uptake of 111In-exendin was determined by drawing regions of interest around the kidneys and in the pancreas. Planar scintigraphic 111In-exendin images of 5 insulinoma patients were used for dosimetry studies estimating the maximum insulinoma absorbed dose that could be achieved without causing radiotoxicity to other organs. Results: Gelofusine reduced the renal accumulation of 111In-exendin-4 by 18.1%, whereas the pancreatic uptake remained unchanged. In 3 of 10 subjects, the kidney uptake was reduced to such an extent that the pancreatic tail could be better discriminated from the kidney signal. Dosimetric estimations suggested that the insulinoma absorbed dose ranges from 30.3 to 127.8 Gy. This dose could be further increased to maximally 156.1 Gy if Gelofusine was used. Conclusion: We have shown that Gelofusine can reduce the renal accumulation of 111In-exendin-4 in humans. This reduction not only allows more accurate qualitative and quantitative analyses of radiolabeled exendin uptake in the tail region of the pancreas but also potentiates the safe delivery of a higher radiation dose to GLP-1R-positive tumors for therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Buitinga M, Jansen T, van der Kroon I, et al. Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients. J Nucl Med. 2018. PMID: 30504139. doi:10.2967/jnumed.118.219980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。